Crinetics Pharmaceuticals, Inc.
CRNX
Classement en actions
#2220
Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical... Crinetics Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical enterprise, dedicated to the identification, advancement, and market introduction of therapeutic solutions for infrequent endocrine conditions and related tumors. Their flagship drug candidate, Paltusotine, is an orally administered, selective, non-peptide somatostatin receptor type 2 agonist. This compound has concluded its Phase III clinical trials for the treatment of acromegaly, and has also completed Phase II trials targeting carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). Furthermore, the company's pipeline includes CRN04777, an oral selective non-peptide somatostatin type 5 receptor agonist, which is currently undergoing Phase I clinical trials for congenital hyperinsulinism. Another investigational drug, CRN04894, an oral adrenocorticotrophic hormone antagonist, is in Phase I clinical trials for Cushing's disease and congenital adrenal hyperplasia. Crinetics Pharmaceuticals, Inc. was founded in 2008 and maintains its headquarters in San Diego, California.
Prix de l'action
$84.95
Dernière synchronisation: 2026-09-01
Capitalisation boursière
$9.00B
Changement (1 jour)
0.00%
Changement (1 an)
110.12%
Pays
US
Échange Crinetics Pharmaceuticals, Inc. (CRNX)
Catégorie
Healthcare
Revenus pour Crinetics Pharmaceuticals, Inc. (CRNX)
Revenus en Jun 2026 TTM : $42.16M
Selon les derniers rapports financiers de Crinetics Pharmaceuticals, Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $42.16M. En 2023, l'entreprise a réalisé un chiffre d'affaires de $4.01M une diminution par rapport à le chiffre d'affaires de l'année 2022, qui était de $4.74M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour Crinetics Pharmaceuticals, Inc. de 2016 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $42.16M | 3,957.36% |
| 2024 | $1.04M | -74.11% |
| 2023 | $4.01M | -15.28% |
| 2022 | $4.74M | 339.42% |
| 2021 | $1.08M | 1,418.31% |
| 2020 | $71.00K | -94.05% |
| 2019 | $1.19M | -50.86% |
| 2018 | $2.43M | 18.73% |
| 2017 | $2.05M | 247.20% |
| 2016 | $589.00K | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 29,846.63% |
US
|
|
| $2.23B | 5,185.13% |
US
|
|
| $15.74B | 37,247.77% |
AU
|
|
| $6.02B | 14,183.35% |
NL
|
|
| - | - |
CH
|
